Megyrina

Megestrol acetate, the active ingredient in Megyrina, is a synthetic progestin presented as an oral tablet for systemic use. It is employed to stimulate appetite and to provide antineoplastic activity in patients with cancer‑related cachexia, advanced breast cancer, and endometrial cancer.

GNH USA supplies Megyrina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution.

Megyrina (megestrol acetate) is used in oncology and HIV‑related conditions to address severe weight loss and hormone‑sensitive tumors.

- Cachexia (cancer or AIDS): helps increase appetite and promote weight gain. - Advanced breast cancer: provides antineoplastic effects by modulating progesterone receptors. - Endometrial cancer: used as hormonal therapy to inhibit tumor progression.

Megyrina may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Weight gain: increased adipose tissue and fluid retention. - Edema: swelling of the lower extremities. - Hypertension: elevated blood pressure. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Adrenal insufficiency: cortisol deficiency after abrupt cessation.

When prescribing Megyrina, clinicians should observe several safety measures.

- Monitor blood glucose: hyperglycemia may develop, especially in diabetic patients. - Check blood pressure regularly: risk of hypertension. - Assess thromboembolic risk: avoid in patients with a history of clotting disorders. - Use caution in hormone‑sensitive cancers: evaluate benefit‑risk ratio. - Review liver function: hepatic impairment may affect metabolism. - Store at room temperature: keep in original container, protect from moisture and light.

Megyrina can interact with other medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase megestrol levels. - Anticoagulants (e.g., warfarin): heightened risk of thrombosis. - Antidiabetic agents (insulin, sulfonylureas): may exacerbate hypoglycemia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - NSAIDs: additive risk of gastrointestinal bleeding. - Hormonal contraceptives: reduced effectiveness due to hormonal interference.